EUVIMEDEUVIMED entdecken
KorrekturKohortenstudie

Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”

Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)

DOI: 10.1002/pds.70522 ↗

Kurz gefasst

Korrektur in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 11.11.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70522

Vancouver

Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70522

BibTeX
@article{euvimed2026,
  title = {Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {11},
  doi = {10.1002/pds.70522}
}
Kostenlos starten →